Literature DB >> 2030148

Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

J Thiele1, H Quitmann, S Wagner, R Fischer.   

Abstract

An immunohistochemical and morphometric analysis was performed on trephine biopsy specimens of the bone marrow in 40 patients (23 men and 17 women, mean age 62 years) with different subtypes of myelodysplastic syndromes (MDS) to determine dysmegakaryopoiesis, but particularly precursor cells--that is, pro- and megakaryoblasts. In 31 of the 40 patients the numbers of megakaryocytes were increased which was associated with a predominance of smaller cell forms (micromegakaryocytes). Compared with periodic acid Schiff, immunostaining with a formalin resistant monoclonal antibody against glycoprotein IIIa (Y2/51(CD61) showed a clinically important proportion of immature elements. These could be designated pro- and megakaryoblasts by taking morphometric measurements on smears and bone marrow sections. There was a relevant increase in the number of promegakaryoblasts in 32 patients, consistent with uncontrolled expansion of the precursor pool. Seventeen repeated bone marrow biopsy specimens taken after chemotherapy largely showed a decrease in the numbers of megakaryocytes including the precursor cell population. Moreover, morphometric evaluation disclosed that micromegakaryocytes in MDS differ significantly from those in chronic myeloid leukaemia (CML) due to distinctive nuclear features and a disturbed nuclear:cytoplasmic ratio. These changes generate a more pleomorphic or atypical appearance of this cell population in MDS, compared with micromegakaryocytes in CML. It is concluded that the disproportionate increase in megakaryocyte precursors and the grossly abnormal aspects of micromegakaryocytes in MDS are characteristics of the severe defect involving haematopoiesis in this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2030148      PMCID: PMC496903          DOI: 10.1136/jcp.44.4.300

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  40 in total

1.  Use of freeze-dried paraffin-embedded sections for immunohistologic staining with monoclonal antibodies.

Authors:  H Stein; K Gatter; H Asbahr; D Y Mason
Journal:  Lab Invest       Date:  1985-06       Impact factor: 5.662

2.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

3.  Classification of myeloproliferative disorders by bone marrow histology.

Authors:  B Frisch; R Bartl; R Burkhardt; K Jäger; G Mahl; G Kettner
Journal:  Bibl Haematol       Date:  1984

4.  Preleukemic myelodysplastic syndromes (MDS): pathogenetical considerations based on retrospective clinicomorphological sequential studies.

Authors:  I Fohlmeister; R Fischer; H E Schaefer
Journal:  Anticancer Res       Date:  1985 Mar-Apr       Impact factor: 2.480

5.  Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes.

Authors:  T Ruutu; S Partanen; R Lintula; L Teerenhovi; S Knuutila
Journal:  Scand J Haematol       Date:  1984-04

6.  Immunological study of in vitro maturation of human megakaryocytes.

Authors:  G Vinci; A Tabilio; J F Deschamps; D Van Haeke; A Henri; J Guichard; P Tetteroo; P M Lansdorp; T Hercend; W Vainchenker
Journal:  Br J Haematol       Date:  1984-04       Impact factor: 6.998

7.  Myelodysplastic syndromes: a study of 101 cases according to the FAB classification.

Authors:  T Vallespi; M Torrabadella; A Julia; D Irriguible; A Jaen; G Acebedo; J Triginer
Journal:  Br J Haematol       Date:  1985-09       Impact factor: 6.998

8.  Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.

Authors:  G Tricot; C De Wolf-Peeters; B Hendrickx; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-07       Impact factor: 6.998

Review 9.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 10.  Chronic myeloproliferative disorders (CMPD).

Authors:  R Burkhardt; R Bartl; K Jäger; B Frisch; G Kettner; G Mahl; M Sund
Journal:  Pathol Res Pract       Date:  1984-11       Impact factor: 3.250

View more
  6 in total

Review 1.  Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.

Authors:  D A Winfield; S V Polacarz
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

Review 2.  Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes.

Authors:  Aikaterini Karagianni; Katya Ravid
Journal:  Blood       Date:  2022-05-26       Impact factor: 25.476

3.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

4.  Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.

Authors:  J Thiele; I Hoffmann; H P Bertsch; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05

6.  Inhibition of Osteoblast Differentiation by JAK2V617F Megakaryocytes Derived From Male Mice With Primary Myelofibrosis.

Authors:  Aikaterini Karagianni; Shinobu Matsuura; Louis C Gerstenfeld; Katya Ravid
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.